Bahk Won-Myong, Yoon Bo-Hyun, Lee Kyoung-Uk, Chae Jeong-Ho
Department of Psychiatry, College of Medicine, The Catholic University of Korea, St Mary's Hospital, 62 Yoido-Dong, Youngdeungpo-Gu, Seoul 150-713, Korea.
Hum Psychopharmacol. 2004 Apr;19(3):181-5. doi: 10.1002/hup.577.
The atypical antipsychotics are being increasingly used to control acute manic episodes, and data are emerging to support their mood-stabilizing and antidepressant properties. This study investigated the short-term efficacy of quetiapine as an add-on therapy in the treatment of acute mania.
This study was a 4-week, open-label, add-on, prospective investigation using quetiapine in addition to mood stabilizers. Data on 18 patients fulfilling DSM-IV diagnostic criteria for bipolar I disorder were analysed. The Young mania rating scale (YMRS), the Hamilton scale for depression (HDRS), the brief psychiatric rating scale (BPRS) and extrapyramidal symptom rating scale (ESRS) were applied at baseline and at weeks 1, 2 and 4. The clinical global impression scale (CGI) was evaluated at baseline and week 4.
The addition of quetiapine produced a statistically significant improvement on the YMRS, HDRS, BPRS and CGI score at week 4 from baseline (p<0.005). Quetiapine was well tolerated, with no subjects discontinuing because of side effects.
The combination of quetiapine was associated with a substantial symptomatic improvement in patients with acute mania. Randomized placebo-controlled prospective studies are needed.
非典型抗精神病药物越来越多地用于控制急性躁狂发作，并且有数据开始支持其心境稳定和抗抑郁特性。本研究调查了喹硫平作为附加疗法治疗急性躁狂症的短期疗效。
本研究是一项为期4周的开放标签、附加的前瞻性调查，除心境稳定剂外还使用喹硫平。分析了18例符合DSM-IV双相I型障碍诊断标准患者的数据。在基线以及第1、2和4周应用Young躁狂评定量表（YMRS）、汉密尔顿抑郁量表（HDRS）、简明精神病评定量表（BPRS）和锥体外系症状评定量表（ESRS）。在基线和第4周评估临床总体印象量表（CGI）。
在第4周时，与基线相比，加用喹硫平使YMRS、HDRS、BPRS和CGI评分有统计学意义的改善（p<0.005）。喹硫平耐受性良好，没有受试者因副作用而停药。
喹硫平联合用药与急性躁狂症患者症状的显著改善相关。需要进行随机安慰剂对照的前瞻性研究。
